Amundi
AMPH icon

Amundi’s Amphastar Pharmaceuticals AMPH Stock Holding History

Amundi’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,925
Closed -$407K – 1675
2025
Q1 		$407K Sell
14,925
-4,658
-24% -$149K ﹤0.01% 1539
2024
Q4 		$717K Buy
19,583
+12,899
+193% +$590K ﹤0.01% 1487
2024
Q3 		$309K Buy
6,684
+662
+11% +$29.1K ﹤0.01% 1543
2024
Q2 		$232K Sell
6,022
-857
-12% -$35.5K ﹤0.01% 1544
2024
Q1 		$266K Buy
6,879
+1,800
+35% +$93K ﹤0.01% 1577
2023
Q4 		$289K Buy
5,079
+86
+2% +$4.52K ﹤0.01% 1545
2023
Q3 		$228K Buy
4,993
+284
+6% +$15.5K ﹤0.01% 1566
2023
Q2 		$271K Sell
4,709
-695
-13% -$30.8K ﹤0.01% 1520
2023
Q1 		$210K Buy
+5,404
New +$177K ﹤0.01% 1556

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Amundi's AMPH Position: Q2 2025 in Review

Amundi sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 14,925 shares — an estimated $407K sold.

Amundi first reported a position in AMPH in Q1 2023 and held it in 9 quarters. The position peaked at $717K in Q4 2024. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • Amundi reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 14,925 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $407K.
  • Amundi first reported a position in Amphastar Pharmaceuticals in Q1 2023 and held it in 9 quarters.
  • Amundi's Amphastar Pharmaceuticals position peaked at $717K in Q4 2024.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.